<p>Allworth Financial LP 在最近向证券交易委员会（SEC）披露的信息中表示，在第四季度将其在辉瑞公司（NYSE:PFE - 免费报告）的股份增加了 63.7%。该公司在本季度额外收购了 138,804 股后，持有该生物制药公司 356,594 股股票。Allworth Financial LP 在辉瑞的持股在最近的报告期末价值为 8,879,000 美元。</p>
<ul>
<li>应对大型制药专利悬崖的两种方式</li>
</ul>
<p>其他一些对冲基金和机构投资者最近也对 PFE 的持仓进行了调整。Horizon Financial Services LLC 在第四季度将其在辉瑞的股份增加了 174.8%。Horizon Financial Services LLC 目前持有 1,014 股辉瑞的股票，价值 25,000 美元，此前在该期间额外收购了 645 股。YANKCOM Partnership 在第四季度新建了辉瑞的持仓，价值约 28,000 美元。Grey Fox Wealth Advisors LLC 在第三季度新建了辉瑞的持仓，价值约 29,000 美元。Darwin Wealth Management LLC 在第二季度新建了辉瑞的持仓，价值约 32,000 美元。最后，Torren Management LLC 在第四季度新建了辉瑞的持仓，价值约 34,000 美元。68.36% 的股票由机构投资者和对冲基金持有。</p>
<h2>辉瑞股票表现</h2>
<p>辉瑞的股票在周五开盘价为 25.31 美元。该公司的流动比率为 1.25，速动比率为 0.94，债务与股本比率为 0.67。该公司的市值为 1,442.5 亿美元，市盈率为 19.32，贝塔值为 0.35。该股票的 50 日移动平均线为 26.98 美元，200 日移动平均线为 26.19 美元。辉瑞公司 12 个月低点为 22.45 美元，12 个月高点为 28.75 美元。</p>
<ul>
<li>5 只高收益股票以保护您的投资组合免受风暴影响</li>
</ul>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近在 5 月 5 日星期二发布了季度财报。这家生物制药公司报告本季度每股收益为 0.75 美元，超出分析师一致预期的 0.72 美元，超出 0.03 美元。该公司在本季度的收入为 144.5 亿美元，而一致预期为 138.4 亿美元。辉瑞的股本回报率为 19.44%，净利润率为 11.83%。辉瑞的收入同比增长 5.4%。去年同期，该公司每股收益为 0.92 美元。辉瑞已将其 2026 财年的指导目标设定为每股收益 2.800-3.000 美元。作为一个整体，卖方分析师预测辉瑞公司在当前年度将发布每股收益 2.99 美元。</p>
<h2>辉瑞分红公告</h2>
<p>该公司最近还宣布了一项季度分红，将于 6 月 12 日星期五支付。5 月 8 日星期五的登记投资者将获得每股 0.43 美元的分红。这相当于年化 1.72 美元的分红和 6.8% 的分红收益率。该分红的除息日为 5 月 8 日星期五。辉瑞的分红支付比率（DPR）目前为 131.30%。</p>
<h2>辉瑞关键新闻</h2>
<ul>
<li>辉瑞因第四季度业绩上涨——但这可能是最重要的催化剂</li>
</ul>
<p>以下是本周影响辉瑞的关键新闻：</p>
<ul>
<li>积极情绪：辉瑞宣布其血友病疗法 Hympavzi 在欧洲的标签扩展，这可能扩大该药物的商业机会并支持长期收入增长。</li>
<li>积极情绪：多项更新强调了持续的临床和开发活动，包括针对 Nurtec ODT 的新韩国偏头痛研究、PF-07799933 的第一阶段食物效应研究、prazosin 的场地转移试验，以及计划中的日本 RSV 疫苗试验。这些都增强了辉瑞的产品线和全球扩展努力。</li>
<li>积极情绪：关于辉瑞第一季度收益的近期评论指出，新产品和收购产品的势头正在改善，尤其是在肿瘤学和偏头痛治疗方面，以及 Seagen 整合和法律和解的进展可能改善未来现金流的清晰度。</li>
<li>中性情绪：媒体报道还指出，投资者情绪仍然复杂，一些分析师和评论员认为辉瑞仍然缺乏强劲的收益势头，更多依赖于其分红和防御性估值，而不是明确的短期增长催化剂。</li>
<li>消极情绪：辉瑞仍面临 COVID 相关销售下降和即将到来的专利到期的担忧，这些因素在收益超出预期后仍对股票造成压力。</li>
</ul>
<h2>分析师升级和降级</h2>
<p>PFE 最近成为多份分析师报告的主题。中金公司研究在 4 月 16 日星期四的研究报告中开始覆盖辉瑞。他们对该股票给予了 “跑赢大盘” 的评级，并设定了 33.00 美元的目标价。BMO Capital Markets 在 3 月 9 日星期一的研究报告中重申了 “跑赢大盘” 的评级，并对辉瑞的股票设定了 30.00 美元的目标价。Wolfe Research 在星期四的研究报告中重申了 “跑输大盘” 的评级，并将辉瑞的目标价设定为 26.00 美元。Weiss Ratings 在 5 月 6 日星期三的研究报告中将辉瑞的评级从 “持有（c-）” 上调至 “持有（c）”。最后，美国银行在 4 月 9 日星期四的研究报告中将辉瑞的目标价从 27.00 美元下调至 26.00 美元，并对该公司设定了 “中性” 评级。一位投资分析师对该股票给予了强烈买入评级，六位给予了买入评级，十二位给予了持有评级，三位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，平均目标价为 28.84 美元。</p>
<p><strong>阅读我们关于 PFE 的最新报告</strong></p>
<h2>辉瑞公司简介</h2>
<p>（免费报告）</p>
<p>辉瑞公司（Pfizer Inc）在纽约证券交易所上市，股票代码为 PFE，是一家总部位于纽约市的跨国生物制药公司。该公司成立于 1849 年，由查尔斯·辉瑞（Charles Pfizer）和查尔斯·厄哈特（Charles Erhart）创立，专注于人类健康的药物和疫苗的研究、开发、生产和商业化。其业务涵盖发现研究、临床开发、监管事务、制造以及多个治疗领域的全球商业分销。</p>
<p>辉瑞的产品组合和研发管线涵盖肿瘤学、免疫学、心脏病学、内分泌学、罕见疾病、医院急救和抗感染药物，以及一个可观的疫苗业务。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比辉瑞更好的股票</li>
<li>维京航运创下历史新高——基本面信号显示未来还有更多</li>
<li>数据库获得关注：现在卖出的五个理由</li>
<li>TMC 股票：为什么这家尚未盈利的矿业公司值得关注</li>
<li>电网正在衰退——是时候购买其替代品了吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

辉瑞

医疗业 ETF - Vanguard

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

美国制药 ETF - iShares

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

<p>Allworth Financial LP 在第四季度将其在辉瑞公司（NYSE:PFE）的持股增加了 63.7%，目前拥有 356,594 股，价值 888 万美元。其他机构投资者也调整了他们在辉瑞的持仓。该公司报告第一季度每股收益为 0.75 美元，超出预期，收入为 144.5 亿美元。辉瑞宣布每股季度分红为 0.43 美元，收益率为 6.8%。尽管有积极的发展，但对 COVID 销售下降和专利到期的担忧仍然存在</p>

<p>Allworth Financial LP increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 63.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 356,594 shares of the biopharmaceutical company's stock after acquiring an additional 138,804 shares during the quarter. Allworth Financial LP's holdings in Pfizer were worth $8,879,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Allworth Financial LP 在最近向证券交易委员会（SEC）披露的信息中表示，在第四季度将其在辉瑞公司（NYSE:PFE - 免费报告）的股份增加了 63.7%。该公司在本季度额外收购了 138,804 股后，持有该生物制药公司 356,594 股股票。Allworth Financial LP 在辉瑞的持股在最近的报告期末价值为 8,879,000 美元。</p>
</div><ul>
<li>2 Ways to Play the Big Pharma Patent Cliff</li>
</ul>
<div class="lb-trans"><ul>
<li>应对大型制药专利悬崖的两种方式</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Horizon Financial Services LLC lifted its stake in shares of Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 645 shares during the period. YANKCOM Partnership acquired a new position in shares of Pfizer in the fourth quarter worth approximately $28,000. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer in the third quarter worth approximately $29,000. Darwin Wealth Management LLC acquired a new position in shares of Pfizer in the second quarter worth approximately $32,000. Finally, Torren Management LLC acquired a new position in shares of Pfizer in the fourth quarter worth approximately $34,000. 68.36% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也对 PFE 的持仓进行了调整。Horizon Financial Services LLC 在第四季度将其在辉瑞的股份增加了 174.8%。Horizon Financial Services LLC 目前持有 1,014 股辉瑞的股票，价值 25,000 美元，此前在该期间额外收购了 645 股。YANKCOM Partnership 在第四季度新建了辉瑞的持仓，价值约 28,000 美元。Grey Fox Wealth Advisors LLC 在第三季度新建了辉瑞的持仓，价值约 29,000 美元。Darwin Wealth Management LLC 在第二季度新建了辉瑞的持仓，价值约 32,000 美元。最后，Torren Management LLC 在第四季度新建了辉瑞的持仓，价值约 34,000 美元。68.36% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Pfizer Stock Performance</h2>
<div class="lb-trans"><h2>辉瑞股票表现</h2>
</div><p>Shares of PFE opened at $25.31 on Friday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $144.25 billion, a price-to-earnings ratio of 19.32 and a beta of 0.35. The stock has a 50 day moving average of $26.98 and a 200 day moving average of $26.19. Pfizer Inc. has a 12 month low of $22.45 and a 12 month high of $28.75.</p>
<div class="lb-trans"><p>辉瑞的股票在周五开盘价为 25.31 美元。该公司的流动比率为 1.25，速动比率为 0.94，债务与股本比率为 0.67。该公司的市值为 1,442.5 亿美元，市盈率为 19.32，贝塔值为 0.35。该股票的 50 日移动平均线为 26.98 美元，200 日移动平均线为 26.19 美元。辉瑞公司 12 个月低点为 22.45 美元，12 个月高点为 28.75 美元。</p>
</div><ul>
<li>5 High-Yield Stocks to Shield Your Portfolio From the Storm</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只高收益股票以保护您的投资组合免受风暴影响</li>
</ul>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer's revenue was up 5.4% on a year-over-year basis. During the same period last year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近在 5 月 5 日星期二发布了季度财报。这家生物制药公司报告本季度每股收益为 0.75 美元，超出分析师一致预期的 0.72 美元，超出 0.03 美元。该公司在本季度的收入为 144.5 亿美元，而一致预期为 138.4 亿美元。辉瑞的股本回报率为 19.44%，净利润率为 11.83%。辉瑞的收入同比增长 5.4%。去年同期，该公司每股收益为 0.92 美元。辉瑞已将其 2026 财年的指导目标设定为每股收益 2.800-3.000 美元。作为一个整体，卖方分析师预测辉瑞公司在当前年度将发布每股收益 2.99 美元。</p>
</div><h2>Pfizer Dividend Announcement</h2>
<div class="lb-trans"><h2>辉瑞分红公告</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's dividend payout ratio (DPR) is presently 131.30%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 6 月 12 日星期五支付。5 月 8 日星期五的登记投资者将获得每股 0.43 美元的分红。这相当于年化 1.72 美元的分红和 6.8% 的分红收益率。该分红的除息日为 5 月 8 日星期五。辉瑞的分红支付比率（DPR）目前为 131.30%。</p>
</div><h2>Key Pfizer News</h2>
<div class="lb-trans"><h2>辉瑞关键新闻</h2>
</div><ul>
<li>Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞因第四季度业绩上涨——但这可能是最重要的催化剂</li>
</ul>
</div><p>Here are the key news stories impacting Pfizer this week:</p>
<div class="lb-trans"><p>以下是本周影响辉瑞的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Pfizer announced a Europe label expansion for its hemophilia therapy Hympavzi, which could broaden the drug’s commercial opportunity and support long-term revenue growth.</li>
<li>Positive Sentiment: Multiple updates highlighted ongoing clinical and development activity, including a new Korea migraine study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, a prazosin site-transfer trial, and a planned Japan RSV vaccine trial. These reinforce Pfizer’s pipeline and global expansion efforts.</li>
<li>Positive Sentiment: Recent commentary around Pfizer’s Q1 earnings pointed to improving momentum in new and acquired products, especially oncology and migraine treatments, as well as progress from the Seagen integration and legal settlements that may improve clarity around future cash flow.</li>
<li>Neutral Sentiment: Media coverage also noted that investor sentiment remains mixed, with some analysts and commentators arguing Pfizer still lacks strong earnings momentum and is being supported more by its dividend and defensive valuation than by a clear near-term growth catalyst.</li>
<li>Negative Sentiment: Pfizer continues to face concerns about declining COVID-related sales and looming patent expirations, which have weighed on the stock even after earnings beat expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：辉瑞宣布其血友病疗法 Hympavzi 在欧洲的标签扩展，这可能扩大该药物的商业机会并支持长期收入增长。</li>
<li>积极情绪：多项更新强调了持续的临床和开发活动，包括针对 Nurtec ODT 的新韩国偏头痛研究、PF-07799933 的第一阶段食物效应研究、prazosin 的场地转移试验，以及计划中的日本 RSV 疫苗试验。这些都增强了辉瑞的产品线和全球扩展努力。</li>
<li>积极情绪：关于辉瑞第一季度收益的近期评论指出，新产品和收购产品的势头正在改善，尤其是在肿瘤学和偏头痛治疗方面，以及 Seagen 整合和法律和解的进展可能改善未来现金流的清晰度。</li>
<li>中性情绪：媒体报道还指出，投资者情绪仍然复杂，一些分析师和评论员认为辉瑞仍然缺乏强劲的收益势头，更多依赖于其分红和防御性估值，而不是明确的短期增长催化剂。</li>
<li>消极情绪：辉瑞仍面临 COVID 相关销售下降和即将到来的专利到期的担忧，这些因素在收益超出预期后仍对股票造成压力。</li>
</ul>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>PFE has been the topic of a number of recent analyst reports. CICC Research initiated coverage on Pfizer in a research note on Thursday, April 16th. They issued an &#34;outperform&#34; rating and a $33.00 price objective on the stock. BMO Capital Markets reaffirmed an &#34;outperform&#34; rating and issued a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. Wolfe Research restated an &#34;underperform&#34; rating and set a $26.00 target price on shares of Pfizer in a research report on Thursday. Weiss Ratings raised Pfizer from a &#34;hold (c-)&#34; rating to a &#34;hold (c)&#34; rating in a research note on Wednesday, May 6th. Finally, Bank of America decreased their target price on Pfizer from $27.00 to $26.00 and set a &#34;neutral&#34; rating for the company in a research note on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of &#34;Hold&#34; and an average target price of $28.84.</p>
<div class="lb-trans"><p>PFE 最近成为多份分析师报告的主题。中金公司研究在 4 月 16 日星期四的研究报告中开始覆盖辉瑞。他们对该股票给予了 “跑赢大盘” 的评级，并设定了 33.00 美元的目标价。BMO Capital Markets 在 3 月 9 日星期一的研究报告中重申了 “跑赢大盘” 的评级，并对辉瑞的股票设定了 30.00 美元的目标价。Wolfe Research 在星期四的研究报告中重申了 “跑输大盘” 的评级，并将辉瑞的目标价设定为 26.00 美元。Weiss Ratings 在 5 月 6 日星期三的研究报告中将辉瑞的评级从 “持有（c-）” 上调至 “持有（c）”。最后，美国银行在 4 月 9 日星期四的研究报告中将辉瑞的目标价从 27.00 美元下调至 26.00 美元，并对该公司设定了 “中性” 评级。一位投资分析师对该股票给予了强烈买入评级，六位给予了买入评级，十二位给予了持有评级，三位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，平均目标价为 28.84 美元。</p>
</div><p><strong>Read Our Latest Report on PFE</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 PFE 的最新报告</strong></p>
</div><h2>Pfizer Company Profile</h2>
<div class="lb-trans"><h2>辉瑞公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.</p>
<div class="lb-trans"><p>辉瑞公司（Pfizer Inc）在纽约证券交易所上市，股票代码为 PFE，是一家总部位于纽约市的跨国生物制药公司。该公司成立于 1849 年，由查尔斯·辉瑞（Charles Pfizer）和查尔斯·厄哈特（Charles Erhart）创立，专注于人类健康的药物和疫苗的研究、开发、生产和商业化。其业务涵盖发现研究、临床开发、监管事务、制造以及多个治疗领域的全球商业分销。</p>
</div><p>Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.</p>
<div class="lb-trans"><p>辉瑞的产品组合和研发管线涵盖肿瘤学、免疫学、心脏病学、内分泌学、罕见疾病、医院急救和抗感染药物，以及一个可观的疫苗业务。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>Viking Sails to All-Time Highs—Fundamentals Signal More to Come</li>
<li>Datavalut Gains Traction: 5 Reasons to Sell Now</li>
<li>TMC Stock: Why This Pre-Revenue Miner Is Worth Watching</li>
<li>The Power Grid Is Dying—Is It Time to Buy Its Replacement?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比辉瑞更好的股票</li>
<li>维京航运创下历史新高——基本面信号显示未来还有更多</li>
<li>数据库获得关注：现在卖出的五个理由</li>
<li>TMC 股票：为什么这家尚未盈利的矿业公司值得关注</li>
<li>电网正在衰退——是时候购买其替代品了吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Allworth Financial LP Has $8.88 Million Stock Holdings in Pfizer Inc. $PFE

- Allworth Financial LP 在第四季度将其对 Pfizer 的持股增加了 63.7%。  
- Pfizer 第四季度收益为 $0.75，每股收入较预期高出 $0.03。  
- Pfizer 宣布将支付 $0.43 的季度股息，年化股息收益率为 6.8%。

Allworth Financial LP 持有辉瑞公司价值 888 万美元的股票